New biologics for food allergy. (PubMed, Curr Opin Allergy Clin Immunol) - Mar 29, 2024 - "Biologics hold promising potential for food allergy treatment. Tailoring therapeutic approaches based on shared decision-making becomes pivotal. While omalizumab remains a significant option, next-generation anti-IgE antibodies and agents targeting alarmins exhibit unique strengths. Dupilumab, despite limited success as monotherapy, shows promise as an adjunct for OIT. Careful consideration of treatment goals, patient preferences, and the evolving landscape of biologics will shape future clinical practice, offering allergists an expanded toolbox for personalized food allergy management."
Journal • Allergy • Food Hypersensitivity • Immunology • IL33 • IL4 • IL4R
|
|
Brent Anderson; Jackson P Schuetz; Sayantani B Sindher
|